Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
Yong‐ho Lee, Yongin Cho, Byung‐Wan Lee, et al.
Diabetes & Metabolism Journal (2019) Vol. 43, Iss. 1, pp. 31-31
Open Access | Times Cited: 145

Showing 1-25 of 145 citing articles:

Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping
Zhipeng Liu, Yang Zhang, Sarah E. Graham, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 2, pp. 263-276
Open Access | Times Cited: 191
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
Eugene Han, Byung‐Wan Lee, Eun Seok Kang, et al.
Metabolism (2024) Vol. 152, pp. 155789-155789
Closed Access | Times Cited: 17
Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Marieke de Vries, Jan Westerink, Karin Kaasjager, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 12, pp. 3842-3853
Open Access | Times Cited: 113
Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
Jingxuan Lian, Jianfang Fu
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 89
Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
Eun‐Jung Rhee
Endocrinology and Metabolism (2019) Vol. 34, Iss. 3, pp. 226-226
Open Access | Times Cited: 88
Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 71
Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy
Jin Yoo, In‐Kyung Jeong, Kyu Jeung Ahn, et al.
Metabolism (2021) Vol. 120, pp. 154798-154798
Closed Access | Times Cited: 68
Recent advances and potentiality of postbiotics in the food industry: Composition, inactivation methods, current applications in metabolic syndrome, and future trends
Yujie Zhong, Tao Wang, Ruilin Luo, et al.
Critical Reviews in Food Science and Nutrition (2022) Vol. 64, Iss. 17, pp. 5768-5792
Closed Access | Times Cited: 48
The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
Jiyun Park, Gyuri Kim, Bongsung Kim, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 40
Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017
Eugene Han, Kyungdo Han, Yong‐ho Lee, et al.
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 3, pp. 347-355
Open Access | Times Cited: 21
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
Stephen A. Harrison, Juan P. Frías, Kathryn Jean Lucas, et al.
Clinical Gastroenterology and Hepatology (2024)
Open Access | Times Cited: 13
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Byung‐Wan Lee, Yong‐ho Lee, Cheol‐Young Park, et al.
Diabetes & Metabolism Journal (2020) Vol. 44, Iss. 3, pp. 382-382
Open Access | Times Cited: 57
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung‐Soo Kim, Byung‐Wan Lee
Clinical and Molecular Hepatology (2020) Vol. 26, Iss. 4, pp. 430-443
Open Access | Times Cited: 55
The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study
Jung‐Min Lee, Yong‐Moon Park, Jae‐Seung Yun, et al.
PLoS ONE (2020) Vol. 15, Iss. 1, pp. e0226351-e0226351
Open Access | Times Cited: 53
Lead, mercury, and cadmium exposures are associated with obesity but not with diabetes mellitus: Korean National Environmental Health Survey (KoNEHS) 2015–2017
Min Kyong Moon, Inae Lee, Aram Lee, et al.
Environmental Research (2021) Vol. 204, pp. 111888-111888
Closed Access | Times Cited: 51
The association of hepatic steatosis and fibrosis with heart failure and mortality
Jiyun Park, Gyuri Kim, Hasung Kim, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 48
Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study
Keishi Ichikawa, Toru Miyoshi, Kazuhiro Osawa, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 41
Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population‐Based Study in Germany
Yvonne Huber, Andreas Schulz, Irene Schmidtmann, et al.
Hepatology Communications (2022) Vol. 6, Iss. 6, pp. 1457-1466
Open Access | Times Cited: 34
Genistein—Opportunities Related to an Interesting Molecule of Natural Origin
Ewa Garbiec, Judyta Cielecka‐Piontek, Magdalena Kowalówka, et al.
Molecules (2022) Vol. 27, Iss. 3, pp. 815-815
Open Access | Times Cited: 28
Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Da Hea Seo, Young Ju Suh, Yongin Cho, et al.
Diabetes & Metabolism Journal (2022) Vol. 46, Iss. 4, pp. 630-639
Open Access | Times Cited: 27
Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
Hye Jin Chun, Eun Ran Kim, Minyoung Lee, et al.
Metabolism (2023) Vol. 145, pp. 155612-155612
Closed Access | Times Cited: 21
Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
Kyung‐Soo Kim, Sangmo Hong, Hong Yup Ahn, et al.
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 2, pp. 220-231
Open Access | Times Cited: 19
Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studies
Patrycja Jakubek, B. Pakuła, Martin Rossmeisl, et al.
Internal and Emergency Medicine (2024) Vol. 19, Iss. 5, pp. 1473-1491
Open Access | Times Cited: 5
Non-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community
Y.B. Park, Kyung Soo Ko, Byoung Doo Rhee
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2758-2758
Open Access
The prevalence of nonalcoholic fatty liver disease in people living with HIV: a systematic review and meta-analysis
Jiaqi Wei, Hui Wei, Yuan Fang, et al.
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top